|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
FR2413974A1
(fr)
|
1978-01-06 |
1979-08-03 |
David Bernard |
Sechoir pour feuilles imprimees par serigraphie
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US5030719A
(en)
|
1986-08-28 |
1991-07-09 |
Teijin Limited |
Cytotoxic antibody conjugates and a process for preparation thereof
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
EP0739904A1
(en)
|
1989-06-29 |
1996-10-30 |
Medarex, Inc. |
Bispecific reagents for aids therapy
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
EP1690935A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
AU8295491A
(en)
|
1990-06-29 |
1992-01-23 |
Biosource Technologies Incorporated |
Melanin production by transformed microorganisms
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
ES2246502T3
(es)
|
1990-08-29 |
2006-02-16 |
Genpharm International, Inc. |
Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
WO1992020373A1
(en)
|
1991-05-14 |
1992-11-26 |
Repligen Corporation |
Heteroconjugate antibodies for treatment of hiv infection
|
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
|
ES2301158T3
(es)
|
1992-07-24 |
2008-06-16 |
Amgen Fremont Inc. |
Produccion de anticuerpos xenogenicos.
|
|
ATE139900T1
(de)
|
1992-11-13 |
1996-07-15 |
Idec Pharma Corp |
Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
|
|
JPH10501681A
(ja)
|
1994-02-22 |
1998-02-17 |
ダナ−ファーバー キャンサー インスティチュート |
核酸送達システムならびにその合成および使用方法
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
CA2219361C
(en)
|
1995-04-27 |
2012-02-28 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
WO1996034096A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US20020029391A1
(en)
|
1998-04-15 |
2002-03-07 |
Claude Geoffrey Davis |
Epitope-driven human antibody production and gene expression profiling
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
JP4958555B2
(ja)
|
2004-09-22 |
2012-06-20 |
協和発酵キリン株式会社 |
安定化されたヒトＩｇＧ４抗体
|
|
AU2010249470B2
(en)
|
2009-05-20 |
2015-06-25 |
Novimmune S.A. |
Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants
|
|
EP2513312B1
(en)
|
2009-12-17 |
2015-03-18 |
NovImmune SA |
Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
|
|
WO2012003028A1
(en)
|
2010-06-29 |
2012-01-05 |
Convatec Technologies Inc. |
Silicone gel adhesives with organic polyhydroxy compounds
|
|
WO2012023053A2
(en)
|
2010-08-16 |
2012-02-23 |
Novimmune S.A. |
Methods for the generation of multispecific and multivalent antibodies
|
|
CN105859889B
(zh)
*
|
2010-11-17 |
2020-01-07 |
中外制药株式会社 |
具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
|
|
US8790651B2
(en)
*
|
2011-07-21 |
2014-07-29 |
Zoetis Llc |
Interleukin-31 monoclonal antibody
|
|
ES2767135T3
(es)
|
2011-10-19 |
2020-06-16 |
Novimmune Sa |
Métodos para purificar anticuerpos
|
|
RU2693078C2
(ru)
|
2012-12-03 |
2019-07-01 |
Новиммун С.А. |
Анти-cd47 антитела и способы их применения
|
|
US9111624B2
(en)
|
2013-03-22 |
2015-08-18 |
Katsuyuki Fujita |
Semiconductor memory device
|
|
US11260117B2
(en)
*
|
2017-05-26 |
2022-03-01 |
Novimmune Sa |
Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
|
|
WO2019016411A1
(en)
|
2017-07-21 |
2019-01-24 |
Novimmune Sa |
GENERATION OF MULTISPECIFIC ANTIBODY MIXTURES AND METHODS OF USE
|
|
CA3084626A1
(en)
*
|
2017-12-04 |
2019-06-13 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof
|
|
CN112566938B
(zh)
*
|
2018-06-03 |
2025-04-01 |
拉姆卡普生物测试有限公司 |
针对ceacam5和cd47的双特异性抗体
|
|
US12448444B2
(en)
*
|
2021-03-22 |
2025-10-21 |
Novimmune Sa |
Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof
|
|
JP2024512574A
(ja)
|
2021-03-22 |
2024-03-19 |
ノビミューン エスアー |
Ｃｄ４７およびｐｄ－ｌ１を標的とする二重特異性抗体ならびにその使用方法
|
|
CA3248133A1
(en)
*
|
2022-01-24 |
2023-07-27 |
Novimmune Sa |
COMPOSITION AND METHODS FOR THE SELECTIVE ACTIVATION OF CYTOKINE SIGNALING PATHWAYS
|
|
EP4490192A1
(en)
*
|
2022-03-07 |
2025-01-15 |
Novimmune S.A. |
Cd28 bispecific antibodies for targeted t cell activation
|
|
AU2023240346A1
(en)
*
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
*
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
AU2023362569A1
(en)
*
|
2022-10-21 |
2025-04-24 |
Novimmune Sa |
Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
|
|
IL328469A
(en)
*
|
2023-11-28 |
2026-07-01 |
Novimmune Sa |
Method for treating disease using antibodies against CD47 and against mesothelin as a single agent and in combination with antibodies against PD-1
|